UNSPSC 51381513: Glafenine hydrochloride

This classification denotes an analgesic agent C19H17ClN2O4.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier MS23T96ZZP, chemically known as benzoic acid, 2-((7-chloro-4-quinolinyl)amino)-, 2,3-dihydroxypropyl ester, hydrochloride (1:1), but more generally known as glafenine hydrochloride, which bears US NIH Compound Identifier 3085326. European Medicines Agency schedules Glafenine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02339MIG.

Most nations, for tariff and trade purposes, schedule glafenine hydrochloride under HS 29334990 and SITC 51575. As of Q4 2014, GLAFENINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: C1CCC(C(C1)C(=O)OCC(CO)O)NC2CCNC3C2CCC(C3)CL.CL.

UNSPSC 51381513 Glafenine hydrochloride is a Commodity code that shows minimal alignment with recent state and local procurement activity. The single opportunity tagged under this code—Seminole County, Florida's IFB60459723LAS for Naloxone and Safe Drug Deactivation Systems—does not involve glafenine hydrochloride or any pharmaceutical product matching the code's nominal scope. Seminole County's solicitation seeks 1,900 units of naloxone and 800 safe drug deactivation systems annually through an IFB posted June 30, 2026, with a response deadline of July 26, 2023, but naloxone is a distinct opioid-reversal agent unrelated to the analgesic glafenine. The mismatch suggests either a tagging error in the county's procurement system or a vendor classification issue rather than genuine market activity under this code.

The code shows no other recent state and local opportunities in the source data. Without a body of recent solicitations, the issuing-body mix, geographic spread, and market characterization cannot be determined. If glafenine hydrochloride procurement occurs in state and local markets, it is not surfacing in this dataset under this UNSPSC tag. Vendors evaluating this code should verify whether it accurately reflects their product classification in state and local procurement databases and consider whether reclassification under a more broadly used pharmaceutical or analgesic code might improve visibility to relevant buyers.